Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Successful treatment of immune thrombocytopenic purpura (ITP) with the thrombopoietin-mimetic Romiplostim

John Meletis, Aikaterini Katsandris, Sophia D. Raptis, Marina Mantzourani

Med Sci Monit 2010; 16(8): CS100-102

ID: 881091

Published: 2010-08-01

Background:    Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis.
    Case Report:    We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient’s platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33×109/l to 96×109/l).
    Conclusions:    Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.

Keywords: Thrombopoietin - therapeutic use, Recombinant Fusion Proteins - therapeutic use, Receptors, Fc - therapeutic use, Humans, Purpura, Thrombocytopenic, Idiopathic - drug therapy, Female, Adult, Treatment Outcome